ATMP clinical trials in the UK

Area of Science:

• Regenerative Medicine
• Biotechnology
• Clinical Trials

Background:

• The UK's Advanced Therapy Medicinal Product (ATMP) clinical trials database tracks the progress of ATMP development.
• CGT Catapult produces this annual database to assess the UK's ATMP landscape.
• This analysis contextualizes UK findings within the global ATMP sector.

Purpose of the Study:

• To highlight key findings from the 2023 UK ATMP clinical trials database.
• To assess the UK's position in the global ATMP clinical development landscape.
• To examine initiatives attracting ATMP developers to the UK.

Main Methods:

• A targeted search of GlobalData's clinical trial database was conducted.
• Trials were refined to include only those investigating products meeting ATMP definitions.
• Each trial was counted once in the analysis to ensure accuracy.

Main Results:

• The number of ongoing UK ATMP clinical trials remained stable, unlike a global 10% decrease.
• Approximately 80% of UK ATMP trials were commercially sponsored.
• Evidence suggests a progression of ATMP trials from early to later phases in the UK.

Conclusions:

• The UK maintains attractiveness for ATMP clinical trials.
• UK government investment, MHRA regulatory support, and the ATTC network foster a positive ATMP development ecosystem.
• These factors contribute to a supportive environment for ATMP developers in the UK.